Submissions and Approvals

Genentech’s Tumor-Agnostic Cancer Drug Approved

The FDA on Thursday approved Genentech’s Rozlytrek (entrectinib) for adults and adolescents who have cancers with a common biomarker — only the third time the agency has approved a cancer treatment on the basis of a biomarker rather than for treatment of a specific tumor. Read More